Medicare Part D sponsors paid pharmacies $587.7 million for some over-the-counter drugs with obsolete prescription-only labels, despite CMS oversight.
Medicare Part D does not cover OTC drugs. According to an Aug. 31 HHS Office of Inspector General report, Part D sponsors made “ineligible” payments for five drugs — more than one year after the brand-name equivalents of those drugs switched from prescription-only to OTC status. The $587.7 million in payments took place from 2021 through 2023.
The payments stemmed from CMS updating its Part D Formulary Reference File based on obsolete FDA data, as well as CMS not establishing a timeline for Part D sponsors to reject these payments for drugs that ended up being OTC.
CMS agreed with OIG’s recommendation to set guidance on timeframes for Part D sponsors to decline payments for OTC drugs improperly sold under prescription-only labeling after a switch.
The FDA released a policy in December 2025 calling on generic drug manufacturers to revise their labeling as soon as possible and within six months following FDA approval to switch a brand-name drug to OTC use.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
